Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sedana Medical"},{"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Receives Approval for European Dossier","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sedana Medical"},{"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Submits IND for US Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sedana Medical"},{"company":"BioArctic AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lecanemab (BAN2401) Phase 2b Study in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research & Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Lecanemab in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Data on Lecanemab to be Presented at Alzheimer's Association International Conference (AAIC)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Lecanemab Presented at The CTAD Alzheimer Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest lecanemab Data to be Presented at The AD\/PD\u2122 Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"}]

BioArctic AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Latest lecanemab Data to be Presented at The AD/PD™ Congress

Details:

BAN2401 (lecanemab), an investigational humanized monoclonal antibody, selectively binds to, neutralize and eliminate soluble toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.

Lead Product(s): Lecanemab

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Eisai

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 11, 2022

ASK
US

Upload
your Pipeline Activity

Sedana Medical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sedana Medical Submits IND for US Clinical Trials

Details:

Sedaconda (isoflurane) for inhaled sedation used in combination with medical device Sedaconda ACD, it's primary endpoint in each study will is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care unit.

Lead Product(s): Isoflurane

Therapeutic Area: Neurology Product Name: Sedaconda

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 24, 2021

ASK
US

Upload
your Pipeline Activity

BioArctic AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

New Data on Lecanemab Presented at The CTAD Alzheimer Conference

Details:

Lecanemab selectively binds to, neutralize and eliminate soluble toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.

Lead Product(s): Lecanemab

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 15, 2021

ASK
US

Upload
your Pipeline Activity

BioArctic AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Latest Data on Lecanemab to be Presented at Alzheimer's Association International Conference (AAIC)

Details:

The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.

Lead Product(s): Lecanemab

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Eisai

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2021

ASK
US

Upload
your Pipeline Activity

Sedana Medical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sedana Medical Receives Approval for European Dossier

Details:

The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.

Lead Product(s): Isoflurane

Therapeutic Area: Neurology Product Name: Sedaconda

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2021

ASK
US

Upload
your Pipeline Activity

BioArctic AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

FDA Grants Breakthrough Therapy Designation for Lecanemab in Alzheimer's Disease

Details:

The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta. In this study, pre-specified analysis showed consistent reduction of clinical decline across several clinical and biomarker endpoints at the highest doses.

Lead Product(s): Lecanemab

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Eisai

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2021

ASK
US

Upload
your Pipeline Activity

BioArctic AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lecanemab (BAN2401) Phase 2b Study in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research & Therapy

Details:

The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment with lecanemab on reducing brain amyloid beta (Aβ) and clinical decline in patients with early Alzheimer's disease.

Lead Product(s): Lecanemab

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2021

ASK
US

Upload
your Pipeline Activity

Sedana Medical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study

Details:

The results indicate that IsoConDa is an effective and safe sedation method and will form the basis for the company's application for European market approval later this autumn.

Lead Product(s): Isoflurane

Therapeutic Area: Neurology Product Name: IsoConDa

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 10, 2020

ASK
US

Upload
your Pipeline Activity

BioArctic AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401

Details:

The enrollment of patients with early Alzheimer's disease will be carried out at memory clinics at four Swedish university hospitals.

Lead Product(s): Ban2401

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY